Work

MicroRNA-21 is a potential therapeutic agent targeting Tgfbi and mitigating high-fat-diet-induced liver disease and cancer

Year: 2025

Type: article

Abstract: expression, and tumor burden in CD-HFD conditions. These findings indicate that miR-21 could serve as an effective strategy to delay or prevent liver disease in HFD environments.

Source: Molecular Therapy — Nucleic Acids

DOI: 10.1016/j.omtn.2025.102752

Authors: Urmila Jagtap, Anan Quan, Yuho Ono, Jonathan D. Lee, Alice Rodrigues, Kylie A. Shen, Sergei Manakov, Gyongyi Szabo, Imad Nasser, Frank J. Slack

Institutions: Beth Israel Deaconess Medical Center, Harvard University, Universidade de São Paulo, Eclipse Bioinnovations (United States)

Language: English

Topic: MicroRNA in disease regulation

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900

Funders: National Institutes of Health, Ludwig Center at Harvard, National Institute on Alcohol Abuse and Alcoholism, National Cancer Institute

Awards: G3734632472, G5790795394, Precision microRNA medicine in cancer

OpenAlex ID: W4415462098

FWCI: 0.978

Cites:

Cited by: 3

Related to: